Drug Trial Radar · NCT04104672
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Nov 6, 2019
Primary completion
Jul 21, 2026
Study completion Jul 21, 2026
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Conditions
- Advanced Pancreatic Cancer
Interventions
AB680Drug
AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
ZimberelimabDrug
Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
Nab-paclitaxelDrug
Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
GemcitabineDrug
Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose date to 90 days after the last dose (approximately 1 year)
- Number of Participants With Dose Limiting ToxicitiesTime frame: From First dose to day 28
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Santa Monica, California
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
New York, New York
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.